Desperate patients get access to experimental Lab-Made vessel

NCT ID NCT07141641

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Humacyte, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This program allows individual patients with vascular disease or end-stage kidney disease on dialysis to request an experimental lab-grown blood vessel (ATEV) if they have no other treatment options and cannot join a clinical study. The vessel is designed to replace or bypass damaged blood vessels for dialysis access. Because this is an expanded access program, it is not a formal trial and is temporarily unavailable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acellular Tissue Engineered Vessel (ATEV)
What this could lead to: If successful, this could provide a new option for patients with vascular disease or kidney failure who need dialysis access but have no other treatment choices.
What could go wrong: This is an expanded access program, not a formal trial, so data is limited. The vessel may fail or cause complications, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE ON DIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL DISEASE ON DIALYSIS VASCULAR DISEASES

More trials for these conditions

Other studies related to the condition(s) this trial covers.